New hope for frail myeloma patients: gentler combo aims to control cancer longer

NCT ID NCT03993912

Summary

This study is testing whether adding a newer drug (daratumumab) to a standard treatment (lenalidomide) works better and is easier to tolerate than the current standard for frail, older adults with newly diagnosed multiple myeloma. The goal is to help control the cancer for a longer time without it getting worse, while possibly causing fewer severe side effects. It is for patients who are not healthy enough for the most intensive chemotherapy treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centre Hospitalier Saint-Malo

    St-Malo, France

  • Centre Hospitalier de Perigueux

    Périgueux, France

  • Centre Hospitalier de Saint Quentin

    Saint-Quentin, France

  • Ch Blois Simone Veil

    Blois, France

  • Ch Chartres Louis Pasteur-Le Coudray

    Le Coudray, France

  • Ch Fleyriat

    Bourg-en-Bresse, France

  • Chi Mont de Marsan Et Pays Des Sources

    Mont-de-Marsan, France

  • Chru Brest Site Hopital Morvan

    Brest, France

  • Chru Jean Minjoz

    Besançon, France

  • Chru Rennes Site Pontchaillou

    Rennes, France

  • Chu Dijon Bourgogne

    Dijon, France

  • Chu Montpellier

    Montpellier, France

  • Chu de Caen Normandie

    Caen, France

  • Chu de Grenoble

    Grenoble, France

  • Chu de Nantes Site Hotel Dieu Hme

    Nantes, France

  • Chu de Nice Hopital de L'Archet

    Nice, France

  • Chu de Tours

    Tours, France

  • Gpe Hospitalier La Rochelle-Re-Aunis

    La Rochelle, France

  • Hopital Haut-Leveque - Chu

    Pessac, 33604, France

  • Hopital Prive Sevigne - Cesson

    Cesson-Sévigné, France

  • Hôpital Claude Huriez, CHU

    Lille, France

  • Institut Paoli Calmettes

    Marseille, France

  • Oncopole Chu Toulouse

    Toulouse, France

Conditions

Explore the condition pages connected to this study.